drugset / Trial / NCT06029829

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

NCT06029829 ↗

Phase 2 Unknown 60 enrolled Xin-Hua Xu
NaSingle-groupOpen-labelTreatment

Summary

Providing more theoretical basis for the prediction of the efficacy of advanced HCC and helping select better advantaged population of HCC immunotherapy to maximize the benefits of patients By exploring the relationship between the changes of PD-1 expression in peripheral blood T lymphocytes and the clinical efficacy before and after the use of PD-1 / PD-L1 inhibitors.

Timeline

Start
2023-01-12
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody — —